NETTACIN

Posology Instil 1 or 2 drops into the conjunctival sac of the affected eye(s) 3 times daily, or according to medical prescription. Paediatric population The safety and efficacy of Nettacin 3 mg/ml eye drops, solution in children aged 3 to 12 years and in adolescents aged 12 to 18 years have not been established.

Method of administration 1. Wash/cleanse your hands thoroughly. 2. Screw the cap down tightly in order to pierce the tip of the bottle. 3. Unscrew the cap, invert the bottle and squeeze it gently so that a single drop falls into the affected eye(s).

Do not allow the tip of the bottle to touch your eye, eyelids or any other surface in order to avoid contamination. 4. Replace and tighten the cap on the dropper bottle. 4). Systemic absorption may be reduced by compressing the lacrimal sac at the medial canthus for a minute during and following the instillation of the drops.

(This blocks the passage of drops via the naso-lacrimal duct to the wide absorptive area of the nasal and pharyngeal mucosa). Duration of treatment The usual duration of treatment is 5 days. The doctor may recommend a longer treatment in the case of refractory or complicated infections.

The reported undesirable effects are listed below according to MedDRA System Organ classification. There is not enough data available to determine the frequency of the individual effects listed (frequency not known): Eye disorders: - eye irritation - conjunctival hyperaemia - eyelid rash - eyelid oedema - eye pruritus Immune system disorders: - hypersensitivity - urticaria Episodes of eye irritation and hypersensitivity caused by Nettacin are mild and transient.

Benzalkonium chloride has been reported to cause eye irritation, symptoms of dry eyes and may affect the tear film and corneal surface. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store).

Serious adverse reactions including neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. 5). Prolonged use of topical antibiotics may determine overgrowth of resistant micro- organisms.

If there is no clinical improvement reported within a relatively short period of time or should any irritation or sensitisation phenomena occur, it is necessary to discontinue therapy and start an appropriate treatment. Nettacin is not injectable, therefore it must not be injected subconjunctivally or introduced in the anterior chamber.

Contact lenses Nettacin 3 mg/ml eye drops, solution in multidose container contains benzalkonium chloride, which is commonly used as a preservative in ophthalmic products. 2 Posology and Method of Administration). Benzalkonium chloride has been reported to cause eye irritation, symptoms of dry eyes and may affect the tear film and corneal surface.

Should be used with caution in dry eye patients and in patients where the cornea may be compromised. Patients should be monitored in case of prolonged use. Close monitoring is required while using Nettacin in patients with conditions where the cornea is compromised, or either the use of Nettacin 3 mg/ml eye drops, solution in single-dose presentation, preservative free should be recommended.

During a superficial eye infection, the usage of contact lenses is strongly discouraged. 2).

1.